Description
Background information
The human respiratory syncytial virus (RSV) is an RNA virus of the paramyxoviridae family. It is the most common cause of viral infections of the lower respiratory tract in infants and young children. The 574 aa fusion protein, also termed Fusion Glycoprotein F0, is a precursor molecule that is cleaved at two sites by a furin-like protease to give rise to the mature F1 and F2 fusion glycoproteins, which subsequently play an important role for viral and plasma cell membrane fusion. Moreover, a bivalent fusion protein analogue is the basis of a newly released RSV vaccine.
The PepTivator RSV-Fusion-Select contains 130 peptides which cover important MHC-I and MHC-II epitopes from F0 protein of both main RS virus subtypes RSV-A [strain A2] and RSV-B [strain B1]. Epitopes derived from the RSV glycoprotein G, matrix -, M2-1 -, RNA-L -, NS1 - as well as nucleoprotein are provided in a separate product, the PepTivator RSV Select.
The PepTivator Peptide Pools have been specially developed for efficient in vitro stimulation of antigen-specific CD4+ and CD8+ T cells in various applications. Stimulation of T cells with PepTivator Peptide Pools causes the secretion of effector cytokines and upregulation of activation markers, which then allows the detection or isolation of antigen-specific T cells.
Quantitative, phenotypical, or functional analysis of antigen-specific T cell immunity can provide important information on the natural course of immune responses in healthy or immunocompromised individuals.
Overview
PepTivator RSV Fusion Select is a pool of lyophilized peptides, covering important MHC-I and MHC-II epitopes from F0 Fusion Glycoprotein of both main RSV subtypes RSV-A [UniProt: P03420] and RSV-B (UniProt: O36634).
In vitro stimulation of antigen-specific T cells with PepTivator Peptide Pools causes the secretion of effector cytokines and the up-regulation of activation markers, which then allow the detection and isolation of antigen-specific T cells.
